• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-3MEF filed

    1/26/21 10:00:23 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care
    Get the next $TRXC alert in real time by email
    S-3MEF 1 transe20210125_s3mef.htm FORM S-3MEF transe20210125_s3mef.htm

    As filed with the Securities and Exchange Commission on January 26, 2021

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ____________________

     

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    ____________________

     

    TRANSENTERIX, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    11-2962080

    (State or Other Jurisdiction of

    (I.R.S. Employer

    Incorporation or Organization)

    Identification Number)

     

    635 Davis Drive, Suite 300

    Morrisville, NC 27560

    (919) 765-8400

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal

    Executive Offices)

    ____________________

     

    Shameze Rampertab

    EVP and Chief Financial Officer

    635 Davis Drive, Suite 300

    Morrisville, NC 27560

    (919) 765-8400

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

    ____________________

     

    With a copy to:

    Mary J. Mullany, Esquire

    Ballard Spahr LLP

    1735 Market Street, 51st Floor

    Philadelphia, PA 19103

    (215) 864-8631

    ____________________

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

     

     

     

    If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

     

    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-236200

     

    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this form is a registration statement filed pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

     

    Large Accelerated Filer

    ☐

    Accelerated Filer

    ☒

    Non-Accelerated Filer

    ☐

    Smaller Reporting Company

    ☒

       

    Emerging Growth Company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

    ____________________

     

    CALCULATION OF REGISTRATION FEE

     

    Title of Securities to be Registered

    Proposed Maximum Aggregate

    Offering Price (1)(2)

    Amount of Registration

    Fee (2)

    Common Stock, par value $0.001 per share

       

    TOTAL

    $13,250,742

    $1,446

     

     

    (1)

    Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).

     

     

    (2)

    Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. TransEnterix, Inc. previously registered an aggregate principal amount of $150,000,000 of the Company’s securities on the Registration Statement on Form S-3 (Registration No. 333-236200), as amended (the “Related Registration Statement”) and paid a fee of $19,470. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of no more than 20% of the maximum aggregate offering price of the remaining securities eligible to be sold under the Related Registration Statement is hereby registered.

     

     

    This registration statement shall become effective upon filing with the Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.

     

     

     

    EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

     

    TransEnterix, Inc. (the “Company”) is filing this registration statement with the Securities and Exchange Commission, or SEC, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. This registration statement relates to the public offering of securities contemplated by the registration statement on Form S-3 (File No. 333-236200), which was originally filed with the SEC on January 31, 2020 and declared effective on February 10, 2020 (the “Prior Registration Statement”).

     

    The Company is filing this registration statement for the purpose registering additional securities of the Company with an aggregate offering price not to exceed $13,250,742. The information set forth in the Prior Registration Statement, including all exhibits thereto and all information incorporated by reference therein, is incorporated by reference in this filing.

     

    The required opinions and consents are listed on the exhibit index and filed with this filing.

     

     

     

    EXHIBIT INDEX

     

    Exhibit

    Number

     

     Description

     5.1

     

     Opinion of Ballard Spahr LLP

     23.1

     

     Consent of BDO LLP

     23.2

     

     Consent of Ballard Spahr LLP (included in Exhibit 5.1)

     24.1

     

     Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Morrisville, State of North Carolina on the 26th day of January, 2021.

     

     

    TransEnterix, Inc.

     

     

     

     

    By:

    /s/ Anthony Fernando

     

     

    Anthony Fernando

     

     

    President and Chief Executive Officer

        (principal executive officer)
         
         
      By: /s/ Shameze Rampertab
        Shameze Rampertab
        Executive Vice President and Chief
        Financial Officer
        (principal financial officer and
        principal accounting officer)

     

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

     

    Title

     

    Date

     

    /s/ Anthony Fernando

     

    President, Chief Executive Officer

    and Director (principal executive officer)

    January 26, 2021

    Anthony Fernando 

         
           

    /s/ Shameze Rampertab

     

    Executive Vice President and Chief

    Financial Officer (principal financial

    officer and principal accounting officer)

    January 26, 2021

    Shameze Rampertab 

         
           

    *

     

    Chairman of the Board and a Director

    January 26, 2021

    Paul A. LaViolette

         
           

    *

     

    Director

    January 26, 2021

    Andrea Biffi

         
           

    *

     

    Director

    January 26, 2021

    Jane H. Hsiao, Ph.D.

         
           

    *

     

    Director

    January 26, 2021

    David B. Milne

         
           

    *

     

    Director

    January 26, 2021

    Richard C. Pfenniger, Jr.

         
           

    *

     

    Director

    January 26, 2021

    William N. Starling, Jr. 

         

     

     

    *By: /s/ Anthony Fernando

      Anthony Fernando

      Attorney-in-fact

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number

     

     

     

    Description

      5.1

         

    Opinion of Ballard Spahr LLP.

    23.1

         

    Consent of BDO USA, LLP.

    23.2

         

    Consent of Ballard Spahr LLP (included in Exhibit 5.1).

    24.1

     

    *

     

    Power of Attorney.

    _____________

    *     Previously filed with TransEnterix, Inc.’s Registration Statement on Form S-3 (File No. 333-236200) originally filed on January 31, 2020.

     

     
    Get the next $TRXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304

    3/4/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical Announces FDA Clearance in General Surgery

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

    3/3/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021. The Company’s presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET. The on-demand conference presentation wil

    3/1/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rampertab Shameze

    4 - TRANSENTERIX, INC. (0000876378) (Issuer)

    2/8/21 8:50:49 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 4: J. C. Anthony Fernando exercised 146,873 units of Common Stock at a strike of $0.00 and disposed of $214,521 worth of Common Stock (67,248 units at $3.19), increasing ownership by 143% to 135,126 units

    4 - TRANSENTERIX, INC. (0000876378) (Issuer)

    2/8/21 8:48:15 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/12/21 4:31:17 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed

    10-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/11/21 5:22:06 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed

    8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/3/21 4:31:01 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - TRANSENTERIX, INC. (0000876378) (Subject)

    2/16/21 9:51:05 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care